Tommy G Thompson bought $326 of TXMD
director at TherapeuticsMD, Inc.. 325 shares at an average of $1.00, traded Apr 14, 2025, filed Apr 15, 2025.
Score components
- +15RoleDirector
- 0Trade size$326 at market
- 0Relative to holdingsHoldings up 2.2%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +40.4%, 3m +9.6%, 6m 0.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000905148-25-001216, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 14, 2025 | POpen-market purchase Common Stock | +325 | $1.00 | $326 | 14,779 | Apr 15, 2025 |
Related signals
Other insiders at TherapeuticsMD, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | TXMDbuy TherapeuticsMD, Inc. | Tommy G Thompson director | $14k 8,400 shares | +57% | |
| 33Weak | TherapeuticsMD, Inc. | Marlan D Walker Chief Executive Officer | $489 490 shares | +1% | |
| 33Weak | TherapeuticsMD, Inc. | Marlan D Walker Chief Executive Officer | $1,994 2,303 shares | +3% | |
| 21Weak | TXMDsell TherapeuticsMD, Inc. | Marlan D Walker Chief Executive Officer | $44k 19,050 shares | -23% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.